我国慢性丙型肝炎(Chronic-hepatitis C，CHC)患者众多、基因型分布复杂、难治型比例高、诊治率低等现状，需探索可及的、治愈率高的泛基因型抗病毒治疗方案。目前，治愈率高且安全性好的直接抗病毒药物(Direct-acting antiviral agents, DAAs)已成为国际丙型肝炎指南的主要推荐治疗方案。拉维达韦(Ravidasvir, RDV)为我国本土原研的新一代NS5A抑制剂，可广泛应用于基因1、2、3、4、6型CHC的治疗，抗病毒活性强，耐药屏障高。多项临床研究显示，RDV与第二代蛋白酶抑制剂达诺瑞韦、核苷类NS5B抑制剂索磷布韦等DAAs联合用于CHC患者治愈率高，安全性良好。本文将对RDV相关研究的结果作一综述。“,”China has largest number of chronic hepatitis C (CHC) patients, with complex distribution of genotypes, high proportion of refractory types and low diagnosis and treatment rate. It is necessary to explore accessible pan-genotype antiviral treatment protocols with high cure rate. Currently, the direct acting antiviral agents (DAAs) are recommended as the main treatment regimes by international guidelines for hepatitis C. Ravidasvir (RDV) is a new generation of NS5a inhibitor, which can be widely used in treatment of gene type 1, 2, 3, 4 and 6 CHC with strong antiviral activity and high resistance barrier. A number of clinical studies demonstrate that the combination of ravidavir with DAAn S, such as second-generation protease inhibitor danoprevir (DNV) and nucleoside NS5b inhibitor sofosbuvir (SOF) have gained high cure rate and good safety for CHC patients. In this article, the results of related studies on ravidavir-based antiretroviral regimens in treatment of CHC are reviewed.n